276 related articles for article (PubMed ID: 33603515)
1. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease.
Huang J; Ou W; Wang M; Singh M; Liu Y; Liu S; Wu Y; Zhu Y; Kumar R; Lin S
Risk Manag Healthc Policy; 2021; 14():491-501. PubMed ID: 33603515
[TBL] [Abstract][Full Text] [Related]
2. Metabolic puzzle: Exploring liver fibrosis differences in Asian metabolic-associated fatty liver disease subtypes.
Shaikh SS; Qazi-Arisar FA; Nafay S; Zaheer S; Shaikh H; Azam Z
World J Hepatol; 2024 Jan; 16(1):54-64. PubMed ID: 38313248
[TBL] [Abstract][Full Text] [Related]
3. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Zhang YC; Lyu ZY; Ma B; Li LM; Wang W; Sheng C; Dai HJ; Huang YB; Song FF; Song FJ; Chen KX
Hepatol Int; 2022 Aug; 16(4):835-845. PubMed ID: 35701716
[TBL] [Abstract][Full Text] [Related]
4. Comparison of MAFLD and NAFLD Characteristics in Children.
Xing Y; Fan J; Wang HJ; Wang H
Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980118
[TBL] [Abstract][Full Text] [Related]
5. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
[TBL] [Abstract][Full Text] [Related]
6. Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes.
Lim TS; Chun HS; Kim SS; Kim JK; Lee M; Cho HJ; Kim SU; Cheong JY
Gut Liver; 2023 Jul; 17(4):610-619. PubMed ID: 36799062
[TBL] [Abstract][Full Text] [Related]
7. Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease.
Cheng YM; Hsieh TH; Wang CC; Kao JH
JHEP Rep; 2023 Sep; 5(9):100836. PubMed ID: 37600956
[TBL] [Abstract][Full Text] [Related]
8. The relationship between skeletal muscle mass to visceral fat area ratio and metabolic dysfunction-associated fatty liver disease subtypes in middle-aged and elderly population: a single-center retrospective study.
Xing M; Ni Y; Zhang Y; Zhao X; Yu X
Front Nutr; 2023; 10():1246157. PubMed ID: 38024359
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
Tang SY; Tan JS; Pang XZ; Lee GH
World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
[TBL] [Abstract][Full Text] [Related]
10. Laparoscopic cholecystectomy: Histopathological analysis of metabolic associated fatty liver disease and fibrosis.
Rodríguez-Antonio I; López-Sánchez GN; Reyes-Gómez VA; Contreras-Flores EH; Farías-García F; Espejel-Deloiza M; Durán-Padilla MA; Chablé-Montero F; Uribe M; Chávez-Tapia NC; Montalvo-Javé EE; Nuño-Lámbarri N
Ann Hepatol; 2022; 27(2):100651. PubMed ID: 34896638
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis.
Fan H; Liu Z; Zhang P; Wu S; Han X; Huang Y; Zhu Y; Chen X; Zhang T
Hepatol Int; 2023 Jun; 17(3):615-625. PubMed ID: 37000387
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
[TBL] [Abstract][Full Text] [Related]
13. Association between Metabolic Dysfunction-associated Fatty Liver Disease and Cognitive Impairment.
Yu Q; He R; Jiang H; Wu J; Xi Z; He K; Liu Y; Zhou T; Feng M; Wan P; Yan H; Xia Q
J Clin Transl Hepatol; 2022 Dec; 10(6):1034-1041. PubMed ID: 36381086
[TBL] [Abstract][Full Text] [Related]
14. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis.
Huang J; Xue W; Wang M; Wu Y; Singh M; Zhu Y; Kumar R; Lin S
Diabetes Metab Syndr Obes; 2021; 14():3417-3425. PubMed ID: 34349535
[TBL] [Abstract][Full Text] [Related]
15. Identification of Hepatic Dendritic Cells in Liver Biopsies Showing Steatosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Associated with Obesity.
Barranco-Fragoso B; Pal SC; Díaz-Orozco LE; Dorantes-Heredia R; Qi X; Méndez-Sánchez N
Med Sci Monit; 2022 Aug; 28():e937528. PubMed ID: 35934868
[TBL] [Abstract][Full Text] [Related]
16. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD.
Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T
Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882
[TBL] [Abstract][Full Text] [Related]
17. Association between serum 25-hydroxy vitamin D level and metabolic associated fatty liver disease (MAFLD)-a population-based study.
Wan B; Gao Y; Zheng Y; Chen R
Endocr J; 2021 Jun; 68(6):631-637. PubMed ID: 33658438
[TBL] [Abstract][Full Text] [Related]
18. Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.
Nguyen VH; Le MH; Cheung RC; Nguyen MH
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2172-2181.e6. PubMed ID: 34033923
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
